Session Abstract – PMWC 2022 Silicon Valley


The PMWC 2021 Data Applications in Clinical Diagnostics Showcase will provide a 15-minute time slot for selected organizations, including commercial companies, clinical testing labs, and medical research institutions, to present their latest advancements, insights, applications, and technologies to an audience of clinicians, leading investigators, academic institutions, pharma and biotech, investors, and potential clients. We will learn about new technologies and findings that promise expedited, cost-effective, and accurate clinical diagnosis for early disease detection, treatment decisions, and disease prevention.

- Clinical Dx/Oncology (including Liquid Biopsy)
- Clinical Dx/Cardio Vascular
- Clinical Dx/Nerodegenerative


Confirmed Presenting Companies:

 Session Chair Profile

M.D., Ph.D., Assistant Professor of Medicine (Oncology), Stanford

Biography
The major focus of Dr. Alizadeh’s research group is to attain a better understanding of the initiation, maintenance, and progression of lymphoid tumors, and their response to existing and novel therapies toward improving current treatment strategies. In this effort, they employ tools from functional genomics, computational biology, molecular genetics, and mouse models. They hope to apply this knowledge towards the design of clinical trials in the treatment of patients with lymphoma, leukemia, and myeloma.


 Speaker Profile

Ph.D., National Segment Director, Neurology, Specialty Medicine, Labcorp

Biography
Dr Volpe graduated from Duke University in 2008 with PhD in computational biology and bioinformatics, with a concentration in immunology. His research involved developing a software algorithm to decipher the germline origins of human immunoglobulin and T-cell receptors and then using that software to analyze large data sets of human antibodies to understand their diversity. He received the American Association of Immunologists-Huang Foundation Young Investigator Award in 2007 for his work in anti-HIV antibody composition. Upon graduating, Dr Volpe worked as a Medical Science Liaison at Monogram Biosciences where he covered the Southeast and Midwest territories. In early 2016 he became the Director of Scientific Outreach, helping to build the Medical Science Liaison team for Labcorp. In early 2018, Dr Volpe began putting together the pieces of what would become Labcorp’s Neurology initiative and he is now the National Segment Director for that program, which covers all of neurology with a focus on neurodegenerative diseases.


Clinical Dx Showcase:
Labcorp

We work day and night, around the world, to deliver answers for all your health questions—whether you’re a provider, drug developer, hospital, medical researcher or patient. That means everything from advancing diagnostic testing, to helping launch new drugs, to offering new perspectives through data, all drawing from a deep well of scientific expertise.

Rule-out Relief: Novel Personalized Alzheimer’s Testing
Biomarkers have long held the promise of deciphering Alzheimer’s disease (AD). Labcorp, in partnership with Cx Precision Medicine, is beginning to fulfill that promise. The test evaluates blood-based biomarkers using a proprietary algorithm to rule patients out of having AD.

 Speaker Profile

Ph.D., CEO, Travera

Biography
Clifford Reid is the founding CEO of Travera. Previously, Dr. Reid was the founding Chairman, President and Chief Executive Officer of Complete Genomics (NASDAQ:GNOM), a leading developer of whole human genome DNA sequencing technologies and services. Prior to Complete Genomics he founded two enterprise software companies: Eloquent (NASDAQ:ELOQ), an internet video company, and Verity (NASDAQ:VRTY), an enterprise search engine company. Dr. Reid is on the Visiting Committee of the Biological Engineering Department at the Massachusetts Institute of Technology (MIT), a member of the MIT Corporation Development Committee, and an advisor to Warburg Pincus. He earned a S.B. in Physics from MIT, an MBA from the Harvard Business School, and a Ph.D. in Management Science and Engineering from Stanford University.


Clinical Dx Showcase:
Travera

Travera has developed a new biomarker for identifying effective cancer drugs and drug combinations for cancer patients.

A Universal Biomarker For Cancer
Travera has developed a new biomarker for identifying effective cancer drugs and drug combinations for cancer patients. Our novel biomarker matches patients with a wide variety of cancers to a wide variety of cancer drugs.

 Speaker Profile

Ph.D., VP, Operations and Data Science, ChromaCode, Inc.

Biography
Dr. MacDonald currently leads ChromaCode’s Data Science and Operations efforts. He is an experienced engineer and manager in the life sciences industry focused on data science, product engineering and process development. He is interested in using modern data science and machine learning approaches to complement tried-and-true industry standard methods for robust design like Design for Six Sigma. His PhD training was in Bioengineering, where he did computational neuroscience work modeling inter-cellular signaling mechanisms in neuro-glial networks at UC San Diego. At Illumina, he was an engineering manager responsible for product engineering and process development for consumables across several major platforms including HiSeqX, helping enable the $1000 genome. He developed numerous tools to monitor and understand the real time performance of worldwide sequencing runs in the cloud and drive continuous product improvement.


Clinical DX Showcase:
ChromaCode, Inc.

ChromaCode is redefining molecular testing through data science by increasing the information content of existing PCR and dPCR tests by 10x, enabling complex precision medicine tests on existing simple, robust technology.

 Speaker Profile

Ph.D., CEO, Arvetas Biosciences

Biography
As an accomplished business executive and 25-year veteran of the biotech sector, Dr. Alan Hauser is leveraging his cross-functional leadership experience to create shareholder value for a UC Irvine spatialomics spinout, Arvetas Biosciences. To cross the chasm from multi-omics innovation to profitability in the marketplace, Alan applies his past success encompassing the technical, intellectual property, marketing, corporate development, and operational aspects of commercializing emerging drug-discovery and diagnostics platforms. With a goal of improving people’s lives, his work directed toward planning, promoting, prospecting, appraising plus ROI-led partnering have contributed to launching 9 genomic products, completing > 65 strategic or revenue-generating alliances, and building 9 biotool businesses, including a Silicon Valley startup’s $189 million IPO. Since obtaining his doctorate in chemical and biomolecular engineering at UC Berkeley, Alan completed the executive program at Northwestern’s Kellogg Management Institute as well as additional finance courses at the University of Chicago and Harvard.


Clinical Dx Showcase:
Arvetas Biosciences

The Arvetas BioSciences single-scan imaging platform, unlike other spatialomic technologies, interrogates the tumor microenvironment of tissue biopsies via RNA/protein detection, so our solution cost-effectively scales as a translational-research and diagnostic tool to enable precision cancer care.

Spatialomics Solution for Disrupting Discovery and Diagnostics
Arvetas BioSciences is addressing significant unmet scientific and medical needs with our multiplexed molecular-marker imaging platform. The single-scan staining solution enables our disparate discovery and diagnostics customers to achieve high-plex spatial transcriptomic and proteomic profiling in an unprecedentedly cost-effective manner.

 Speaker Profile

Ph.D., Director (Clinical R&D), Claret Bioscience

Biography
Dr. Varsha Rao is the Director of Clinical R&D at ClaretBio. She oversees the clinical applications of the novel next-generation sequence assays and analytical pipelines developed at ClaretBio with a main focus on evaluating the utility of cell-free DNA fragmentation patterns in cancer progression and treatment response monitoring. Before joining ClaretBio, she was a Research Scientist at Stanford University School of Medicine in Prof Michael Snyder’s lab. As a part of multiple consortia such as the Integrative Personalized Omics Profiling Project, the Human Microbiome Project and the NASA Twins Study she has worked on longitudinal multiomic analyses, focusing on applying transcriptomics and liquid biopsy approaches to understand nuances of metabolic diseases, cancer, infectious disease and general health. She received her PhD in Molecular and Cellular Biology from University of Maryland Baltimore County in 2012.


Clinical Dx Showcase:
Claret Bioscience

Claret Bioscience’s mission is to improve the quality of NGS data obtained from degraded, highly fragmented, and low yield samples. Our approach aims to provide a complete picture of cfDNA molecules, enhancing the sensitivity of disease screenings, and ultimately improving treatment decisions.

cfDNA Fragmentomic Approach to Precision Oncology
We describe a new approach for cancer disease monitoring that leverages cell-free DNA fragmentation patterns - looking beyond traditional rare somatic mutation detection - with a specific focus on our novel single-stranded library preparation method, SRSLY.

 Speaker Profile

Ph.D., CTO, Genomill Health

Biography
Manu Tamminen is an expert in molecular biology, next- generation DNA sequencing and bioinformatics. He received his PhD from the University of Helsinki and did his post-doctoral research at MIT and ETH Zürich, where he developed methodologies for single cell sequencing and molecular counting. He is currently an Adjunct Professor and Senior Lecturer of Genetics at the University of Turku and has authored several high-impact research publications.


Clinical Dx Showcase:
Genomill Health

Genomill Health Inc is a precision diagnostics company with a mission to revolutionize liquid biopsies with their patent-pending Geno1 technology.

Geno1 Permits Highly Scalable Liquid Biopsies
Liquid biopsies are revolutionizing cancer diagnostics but currently suffer from high cost, limited scalability and long turn-around times. Geno1 is a minimalistic, ligation-based workflow which harnessed next-generation DNA sequencing to provide infinitely scalable molecular quantification for liquid biopsies and beyond.

 Speaker Profile

Ph.D., National Segment Director, Neurology, Specialty Medicine, University of North Texas Health Science Center

Biography
Dr. O’Bryant is the Executive Director of the UNTHSC Institute for Translational Research and Endowed Chair in Pharmacology and Neuroscience. He has spent his entire career working towards the development and implementation of a precision medicine model for advanced diagnostics and therapeutics to better the lives of those suffering from Alzheimer’s disease and other neurodegenerative diseases. He created the AD Blood Test for primary care doctors, which has been validated across multiple cohorts, technologies as well as human and animal models. He has also created a Parkinson’s Disease Blood Test for primary care, a Dementia with Lewy Bodies Blood Test for primary care, as well as an AD Blood Test for adults with Down Syndrome for primary care. He has created multiple technologies to identify subsets of patients suffering from Alzheimer’s disease (and other neurodegenerative diseases) that will benefit from targeted interventions. He is the PI of the HABLE study, which is a community-based study of Alzheimer’s Disease pathology among a multi-ethnic cohort with the goal of identifying and eliminating health disparities through a precision medicine approach. He is PI of the Alzheimer’s Disease in Primary Care (ADPC) study, which is the first-ever study of blood-based biomarkers for screening AD in primary care settings. He has published approximately 200 peer-reviewed publications and has been responsible for nearly $100m in funded research and clinical programs.


 Speaker Profile

VP, Oncology services and Laboratory Collaborations, NeoGenomics

Biography
Ryan Angell has 17 years of diagnostic and healthcare experience with a focus on the design, implementation and management of laboratory outreach programs, internalized test segments, unification of Reference lab contracts and services, cost center optimization with a focus on strategic reduction in lab expenses through managed care strategies and cost containment, loss reduction related to CMS cuts and regulations, and utilization of various tech-only service offerings available through the NeoGenomics suite of services. In addition, Ryan has Extensive experience in coordinating and negotiating enterprise level agreements with large hospital systems, cancer centers, and Oncology Managements organizations across the US.


Clinical Dx Showcase:
NeoGenomics

NeoGenomics is leading cancer reference laboratory serving oncologists and pathologists. A Lab Collaboration with NeoGenomics is a business collaboration working with a dedicated team to help customize a long-term, multi-phase laboratory internalization strategy. We provide extensive turn-key services to evaluate and identify the appropriate lab methodologies for internalization, assist in the unification of your reference lab solutions and aid in your ability to optimize patient care.

Precision Medicine and Laboratory Collaboration with NeoGenomics/ Trapelo Health
A partnership model that implements the use of the Trapelo Decision Support tool and Provides resources to internalize complementary lab methodologies.

 Speaker Profile

Ph.D., Chief Product Officer, Trapelo Health

Biography
Russell Ingersoll has 25 years of healthcare experience and proven success with the design and commercialization of information-based technology products for the clinical and life science industries. He has led product strategy and development at Trapelo Health since 2010. Under his leadership, the company developed clinical informatic tools and processes to build and maintain an evidence-based precision medicine knowledgebase. This knowledgebase now serves as the foundation of Trapelo, the first interoperable platform that enables real-time decision support, treatment selection and reimbursement assurance at the point of care. Prior to joining Trapelo Health, Russ served as VP of Product Development for MedTrust Online, an oncology-centric information portal; Senior Director of Business Development at Phylogeny, Inc., a functional genomics services company; co-Founder of Folio Biosciences, a biobank of clinically annotated specimens and co-founder of BioProtocol, an interactive laboratory protocol system for the research community.


Clinical Dx Showcase:
Trapelo Health

Trapelo Health is a health technology company on a mission to address the challenges that result from rapid changes in the science, technology and business of next-generation cancer care. Its product, Trapelo, is a win-win solution for doctors, labs and payers that need real-time, evidence-based information and full transparency to make patient-based decisions faster. As part of this commitment, Trapelo founded The Precision Medicine Podcast.

Precision Medicine and Laboratory Collaboration with NeoGenomics/ Trapelo Health
A partnership model that implements the use of the Trapelo Decision Support tool and Provides resources to internalize complementary lab methodologies.

 Speaker Profile

TBA

Biography
TBA


 Speaker Profile

TBA

Biography
TBA


 Speaker Profile

TBA

Biography
TBA


 Speaker Profile

TBA

Biography
TBA


 Speaker Profile

Ph.D., Chief Scientific Officer, Foundation Medicine

Biography
Dr Hegde is responsible for diagnostic product development and innovation in next generation technologies. Prior to joining FMI, she spent 14 years at Genentech as head of the clinical translational science and biomarker efforts for Cancer Immunotherapy. She received her postdoctoral education in genomics from The Institute for Genomic Research (TIGR) and graduate education from SUNY, Buffalo.


 Speaker Profile

Ph.D., CEO, BillionToOne Inc.

Biography
At BillionToOne, Oguzhan co-developed a molecular counter platform that increases the resolution of cell-free DNA diagnostics by over a thousandfold. This technology was used to develop BillionToOne’s single-gene NIPT, which is the only (and fastest-growing) test that can detect the most common inherited disorders such as sickle cell disease, cystic fibrosis, and spinal muscular atrophy in the fetus directly from maternal blood. Oguzhan led BillionToOne through Y Combinator and raised a total of more than $90M in funding including from venture capital funds and investors who previously invested in companies such as SpaceX, Uber, Box, Spotify, Palantir, Braintree, WebMD, and Omada Health. Previously, Oguzhan received his PhD from Stanford, where his work was published on the Cover of Cell Systems, and graduated summa cum laude and Phi Beta Kappa from Princeton University with a Bachelor’s in Molecular Biology and minors in Physics, Computer Science, and Applied Mathematics.


Clinical Dx Showcase:
BillionToOne Inc.

BillionToOne is a precision diagnostics company with the mission to make molecular diagnostics more powerful, accurate, and accessible for all. Our QCT molecular counting platform enables us to offer unique products from single-gene NIPT to quantitative liquid biopsy for treatment monitoring.

Molecular Counting Enables High-resolution Liquid Biopsy Panel for Cancer Treatment Monitoring
We describe a novel pan-cancer liquid biopsy panel that quantifies the changes in cell-free tumor DNA level at the single-molecule resolution in cancer patients, without the need to customize the panel.

 Speaker Profile

Ph.D., CEO and CSO, C2i Genomics

Biography
Dr. Asaf Zviran brings 15+ years of R&D management in biology and defense.To date he has managed to publish 13 papers with over 1,700 citations (including Nature and Stem Cell). Asaf received multiple awards and grants. He is an IDF R&D Officer (Captain) with a PhD in Molecular Biology.


Clinical Dx Showcase:
C2i Genomics

C2i Genomics is the first company to develop post-surgery monitoring of cancer recurrence and progression by analyzing subtle changes in the pattern of the tumor’s DNA.

C2i’s Cancer Recognition for Personalized Treatment Monitoring
C2i’s SaaS solution utilizes a cloud-based platform to perform cancer tumor burden monitoring on a global scale, leveraging low-input blood (only 2mL blood) whole-genome sequencing to provide high precision personalized medicine, reduced cancer treatment costs, and accelerated drug development.

 Speaker Profile

TBA

Biography
TBA


 Speaker Profile

TBA

Biography
TBA


 Speaker Profile

Ph.D., Chief Scientific Officer, Exosome Diagnostics

Biography
Johan Skog is a renowned, well-published thought leader in exosome science having pioneered breakthrough discoveries about exosomes and other micro vesicles and their vital role as cell messengers and disease proliferators. While at Massachusetts General Hospital/Harvard Medical School, Dr. Skog discovered that tumor-derived mutations can be detected in exosome RNA from serum and other biofluids, findings which were published in Nature Cell Biology in 2008. Additionally, he demonstrated that exosomes serve to deliver messages to other cells, inducing changes favorable to the proliferation of cancer. Dr. Skog is the inventor of several novel exosome isolation platforms that are used clinically and has over 138 applications/divisional/or granted patents in the exosome field. He continues to expand the research on exosome biology and lead critical advancements in diagnostics, including the world’s first exosome-based diagnostic tests that have now helped over 60,000 patients.


Clinical Dx Showcase:
Exosome Diagnostics

Exosome Diagnostics, a Bio-Techne brand, is a world leader in developing liquid biopsy-based diagnostics.with clinical laboratories in Waltham, MA (US) and Munich (DE) to support its diagnostics and biopharma segments.

Exosomes: New Standard In Multi-Analyte Liquid Biopsy Testing

 Speaker Profile

Ph.D., Sr. Director, Product Development, Invivoscribe

Biography
Dr. Ying Huang has over 25 years of research and industry experience with a broad knowledge in technology and assay development. Ying is passionate about developing novel methods using cutting edge technologies to improve lives with precision diagnostics. Her current work involves applying Invivoscribe assays to MRD detection in hematologic disease samples. Prior to Invivoscribe, she worked at Illumina, Acea Biosciences, Nanogen and MD Anderson Cancer Center. In those roles, she developed a variety of methods ranging from isolating CTC using microfluidic devices to detecting biowarfare agents using electronic microarray. She is co-author of more than 60 publications and abstracts and is co-inventor of 9 patents. Ying received her Ph.D in Electrical Engineering from Bangor University, UK.


Clinical Dx Showcase:
Invivoscribe

Invivoscribe is a global leader in hemato-oncology diagnostics. Our flow & molecular assays, reagents, controls, bioinformatics & services focus on actionable biomarkers supporting therapeutic decisions, MRD testing, stratification & CDx development.

AML MRD Testing Using Flow and NGS
MRD has become an important role as potential diagnostic, prognostics, efficacy-response and monitoring biomarker in AML. Invivoscribe offers complementary AML MRD testing using a comprehensive 12-color flow cytometry assay and a 53-gene NGS panel with limited primary samples.

 Speaker Profile

TBA

Biography
TBA


 Speaker Profile

M.D., Chief Medical Officer, Adela

Biography
Dr. Hartman is a highly trained medical oncologist with 15 years of industry experience in product development with expertise in the clinical development and commercialization of molecular diagnostics in cancer screening and oncology. With an interest in innovative technology platforms to improve patient outcomes and health care, Dr. Hartman has played a pivotal role in the development and commercialization of several molecular diagnostic tests in oncology. This includes leading the design and completion of several large scale clinical trials in early cancer detection and hereditary cancer screening. Her interest in innovative technology ultimately led her to co-found Adela to develop a best-in-class liquid biopsy test for early cancer detection and minimal residual disease detection that avoids the limitations of standard liquid biopsy approaches.


Clinical Dx Showcase:
Adela

Adela is focused on the detection of cancer through a best-in-class liquid biopsy test. Adela's methylome profiling platform has the potential to detect and classify underlying disease, including tissue of origin and histologic subtype.

Pan-Cancer Screening Using Adela’s Methylome Profiling Platform
cfMeDIP-seq is a next-generation methylation technology being developed for applications across the cancer care continuum. Technical advantages enable high sensitivity for cancer detection, tissue of origin, histologic subtyping , and identification of underlying biology through distinct patterns of methylation across the cancer methylome.